Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V B Mychka

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Terapevticheskii Arkhiv|August 12, 2009
[Affection of target organs in hypertensive patients with and without metabolic syndrome]G Kh Sharipova, M A Saidova, T V Balakhonova, et al.
Terapevticheskii Arkhiv|August 31, 2004
[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk]I E Chazova, V B Mychka, K M Mamyrbaeva, et al.
Terapevticheskii Arkhiv|May 11, 2005
[Body mass loss due to orlistat therapy and multiple factors of cardiovascular risk]V B Mychka, V V Gornostaev, D M Ataullakhanova, et al.
Terapevticheskii Arkhiv|January 1, 1996
[The prolonged-action form of Lomir (isradipine) in the treatment of mild and moderate essential hypertension]V V Dmitriev, G G Arabidze, O N Epifanova, et al.
Kardiologiia|September 16, 2008
[Heart rate variability dynamics during treatment of arterial hypertension]G V Riabykina, I E Chazova, V B Mychka, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Terapevticheskii Arkhiv|August 12, 2009
[Affection of target organs in hypertensive patients with and without metabolic syndrome]G Kh Sharipova, M A Saidova, T V Balakhonova, et al.
Terapevticheskii Arkhiv|August 31, 2004
[Cerebrovascular complications in metabolic syndrome: possible approaches to decrease risk]I E Chazova, V B Mychka, K M Mamyrbaeva, et al.
Terapevticheskii Arkhiv|May 11, 2005
[Body mass loss due to orlistat therapy and multiple factors of cardiovascular risk]V B Mychka, V V Gornostaev, D M Ataullakhanova, et al.
Terapevticheskii Arkhiv|January 1, 1996
[The prolonged-action form of Lomir (isradipine) in the treatment of mild and moderate essential hypertension]V V Dmitriev, G G Arabidze, O N Epifanova, et al.
Kardiologiia|September 16, 2008
[Heart rate variability dynamics during treatment of arterial hypertension]G V Riabykina, I E Chazova, V B Mychka, et al.
Pageof 2